UK Regulator Reports 150,000 Adverse Events and 153 Deaths Linked to Weight-Loss Jabs
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Cancers
DiseaseDisease Profile
Cancers are diseases in which abnormal cells divide uncontrollably and can invade nearby tissues or spread to other parts of the body. Cancer can arise in almost any tissue or organ and encompasses many distinct disease types.
- Category
- cancer
- Prevalence
- Common
- C00-C97
Related News
NEOK Bio Doses First Patients in Phase 1 Trials of Bispecific ADCs NEOK001 and NEOK002
NEOK Bio dosed first patients in Phase 1 trials of lead bispecific ADCs NEOK001 and NEOK002 for advanced solid tumors. The candidates target B7-H3/ROR1 and EGFR/MUC1, with initial data expected in 2027.
Four-Week Diet Changes Reduce Biological Age in Older Adults
A four-week dietary intervention reduced biological age in adults aged 65-75, with the strongest effect from an omnivorous high-carbohydrate diet. The Aging Cell study used 20 biomarkers. Longer-term research is needed.
20/20 BioLabs Lists on Nasdaq and Signs U.S. License Deal With ROKIT Healthcare
20/20 BioLabs began trading on Nasdaq under ticker AIDX and disclosed a contingent financing agreement of up to $40 million. It later signed an exclusive U.S. license deal with ROKIT to add CKD prediction to OneTest for Longevity.
BridgeBio shares rise on Phase 3 FORTIFY data for BBP-418 in LGMD2I/R9
BridgeBio shares rose 2.10% to $69.41 after Phase 3 FORTIFY interim data for oral BBP-418 in LGMD2I/R9 showed broad efficacy and placebo-matched safety. The company plans a U.S. FDA filing in H1 2026.
Zentalis selects 400 mg azenosertib regimen for Cyclin E1-positive ovarian cancer
Zentalis selected a 400 mg once-daily, 5-days-on/2-days-off azenosertib regimen for Cyclin E1-positive platinum-resistant ovarian cancer after a DENALI Phase 2 interim analysis. The regimen is planned for DENALI and ASPENOVA as the company pursues a potential accelerated approval pathway.
Sift Biosciences closes $3.7 million pre-seed financing for T-cell booster platform
Sift Biosciences closed an oversubscribed $3.7 million pre-seed round to advance a peptide immunotherapy platform designed to activate pre-existing memory T cells. The financing will fund in vivo studies, expansion of its AI-powered discovery engine, and oncology lead selection.
AI-Driven Precision Medicine Market to Reach $9.7 Billion by 2035
The AI-driven precision medicine market is projected to grow from $0.7 billion in 2025 to $9.7 billion by 2035 at a 26.8% CAGR. North America dominates with 62-67% market share, while machine learning accounts for 39% of the market. The market is moderately consolidated with the top five players controlling over 64% share.
Lipid Nanoparticles Achieve Pancreatic-Targeted mRNA Delivery in Multiple Animal Models
Researchers developed pancreatic-targeted lipid nanoparticles (AH-LNP) that enable precise mRNA delivery to the pancreas through capsule-filter-mediated accumulation. The platform demonstrated efficacy in genome editing and cancer immunotherapy across multiple animal models including non-human primates.
PDS Biotech Amends Phase 3 Trial Protocol to Enable Accelerated Approval Pathway
PDS Biotechnology adopted an amended protocol for its Phase 3 VERSATILE-003 trial, adding progression-free survival as an interim primary endpoint to support potential accelerated approval of PDS0101 in HPV16-positive head and neck cancer.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07292038 |
Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT06416267 |
Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL) |
NOT_YET_RECRUITING | |
| NCT06046066 |
A Phase 1 Study of NM6603 in Advanced Solid Tumors |
TERMINATED | PHASE1 |
| NCT05299710 |
Ovarian Tissue Cryopreservation in Pre-Pubertal (OTC-Pre Pubertal) |
RECRUITING | |
| NCT04198896 |
The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC) |
COMPLETED | |
| NCT03378895 |
CEPPPIA Pilot. Experimental Center of Participative and Individualized Predictive Prevention in Auvergne |
COMPLETED | NA |
| NCT02734303 |
Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test |
COMPLETED | |
| NCT01646437 |
The International Polycap Study 3 (TIPS-3) |
COMPLETED | PHASE3 |
| NCT01441674 |
Animal Assisted Therapy in a Pediatric Setting |
COMPLETED | PHASE1/PHASE2 |
| NCT01295658 |
Cancer Survivor Registry: The Breast Cancer M.A.P. (Mind Affects the Physical) Project |
COMPLETED |